Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.98 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 135.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| MRVI | VIG | |
|---|---|---|
Market Cap | $977.37M | $132.40B |
Volume | 2,742,564 | 893,381 |
Sector | Health | — |
52-Week High | $9.00 | $246.61 |
52-Week Low | $2.83 | $210.70 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VIG trades at $239.71, down slightly by 0.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF focuses on dividend growth stocks with a requirement for 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights VIG's 7.5% quarterly dividend increase and its strategic exclusion of high-yield stocks to prioritize sustainable growth.
The outlook for VIG remains positive given its quality dividend growth strategy and historical 10% annual returns, though the current RSI near 90 suggests short-term overbought conditions. Key risks include sensitivity to interest rate changes and slower dividend growth rates. Analyst sentiment is generally favorable, emphasizing VIG's role in long-term wealth building despite its modest yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
